These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20116128)

  • 1. Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
    Keith RL; Karoor V; Mozer AB; Hudish TM; Le M; Miller YE
    Lung Cancer; 2010 Oct; 70(1):37-42. PubMed ID: 20116128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice.
    Keith RL; Miller YE; Hudish TM; Girod CE; Sotto-Santiago S; Franklin WA; Nemenoff RA; March TH; Nana-Sinkam SP; Geraci MW
    Cancer Res; 2004 Aug; 64(16):5897-904. PubMed ID: 15313935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.
    Nemenoff R; Meyer AM; Hudish TM; Mozer AB; Snee A; Narumiya S; Stearman RS; Winn RA; Weiser-Evans M; Geraci MW; Keith RL
    Cancer Prev Res (Phila); 2008 Oct; 1(5):349-56. PubMed ID: 19138979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer.
    Keith RL; Miller YE; Hoshikawa Y; Moore MD; Gesell TL; Gao B; Malkinson AM; Golpon HA; Nemenoff RA; Geraci MW
    Cancer Res; 2002 Feb; 62(3):734-40. PubMed ID: 11830527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
    Zerbe LK; Dwyer-Nield LD; Fritz JM; Redente EF; Shroyer RJ; Conklin E; Kane S; Tucker C; Eckhardt SG; Gustafson DL; Iwata KK; Malkinson AM
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):605-20. PubMed ID: 18030469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARĪ³ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARĪ³/PTEN/Akt pathway.
    Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
    Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
    Shaw PH; Maughan TS; Clarke AR
    Br J Cancer; 2011 Aug; 105(5):649-57. PubMed ID: 21811251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
    Yan Y; Lu Y; Wang M; Vikis H; Yao R; Wang Y; Lubet RA; You M
    Mol Cancer Res; 2006 Dec; 4(12):971-81. PubMed ID: 17189387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
    Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.
    Ohashi K; Takigawa N; Osawa M; Ichihara E; Takeda H; Kubo T; Hirano S; Yoshino T; Takata M; Tanimoto M; Kiura K
    Cancer Res; 2009 Sep; 69(17):7088-95. PubMed ID: 19690148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
    Ninomiya T; Takigawa N; Ichihara E; Ochi N; Murakami T; Honda Y; Kubo T; Minami D; Kudo K; Tanimoto M; Kiura K
    Mol Cancer Ther; 2013 May; 12(5):589-97. PubMed ID: 23443806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
    Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
    Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
    Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
    Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.